IDEXX reported a strong Q2 2026 with 9% organic growth, driven by 10.3% growth in CAG Diagnostics recurring revenues despite declining clinic visits. The company raised its full-year revenue and EPS guidance, citing strong innovation adoption (InViewDX, CancerDx, Catalyst menu expansions) and momentum in both US and international markets. Reported Q2 revenue growth of ~10% (9% organic) and EPS of $4.27 (up 15% comparable).
IDEXX reported a strong Q2 2026 with 9% organic growth, driven by 10.3% growth in CAG Diagnostics recurring revenues despite declining clinic visits. The company raised its full-year revenue and EPS guidance, citing strong innovation adoption (InViewDX, CancerDx, Catalyst menu expansions) and momentum in both US and international markets. Reported Q2 revenue growth of ~10% (9% organic) and EPS of $4.27 (up 15% comparable).
IDEXX reported a strong Q2 2026 with 9% organic growth, driven by 10.3% growth in CAG Diagnostics recurring revenues despite declining clinic visits. The company raised its full-year revenue and EPS guidance, citing strong innovation adoption (InViewDX, CancerDx, Catalyst menu…
Reported Q2 revenue growth of ~10% (9% organic) and EPS of $4.27 (up 15% comparable).
Guidance · revenue to $4.7225B
Management expressed confidence in strong execution, raised full-year guidance, and highlighted broad-based momentum across segments and innovations.
Management highlighted AI-powered results as a key driver of InViewDX, with the platform's objective AI-powered results and automated menu updates positively impacting customer adoption and utilization.
U.S. same-store clinical visits declined 1.3%. Management expressed confidence in strong execution, raised full-year guidance, and highlighted broad-based momentum across segments and innovations.
Management expressed confidence in strong execution, raised full-year guidance, and highlighted broad-based momentum across segments and innovations.
“U.S. same-store clinical visits declined 1.3% in the quarter, reflecting an IDEXX U.S. Cag Diagnostics recurring revenue growth premium to U.S. clinical visits of approximately 1,100 basis points.”
“the overall consumable revenue performance on InViewDX is comfortably within the range that we discussed around $3,500 to $5,500 per instrument.”
“over 20% of CancerDx orders come from practices using a competitive lab, an indication that clinicians are prioritizing their patients' needs.”
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $14.69–$14.94 | $14.81 | RAISED |
| Op margin | FY2026 | 32.3%–32.5% | 32.4% | RAISED |
| Revenue | FY2026 | $4.7B–$4.745B | $4.7225B | RAISED |
| UnitsINVIEW_DX | FY2026 | 5500 | 5500 | MAINTAINED |
IDEXX's growth is now decoupled from clinic visit counts, driven by diagnostics intensity per visit and aging pet demographics. — This highlights that diagnostics utilization growth can persist despite flat/declining sector visit volume, a key factor for animal health peers.
… related to equivalent days, and average global net price improvement of approximately 4%. As expected, CAG diagnostic instrument revenues declined 20% organically as we lapped the broad commercial availability of NVU DX in the prior year period. U.S. organic CAG diagnostics' recurring revenues grew nearly 10% in Q2, including strong volume gains and net price realization aligned with our full year expectations. U.S. same-store clinical visits declined 1.3% in the quarter, reflecting an IDEXX U.S. Cag Diagnostics recurring revenue growth premium to U.S. clinical visits of approximately 1,100 basis points. Pressure on wellness visits remains the primary constraint to clinical visits, with non-wellness visits showing modest growth. We continue to see growth in pets five years and older across both categories. IDEXX benefits from quality of clinical visits. with an increasing number including diagnostics and broader use of diagnostic testing menu. With a substantial majority of wellness visits today not including blood work, we see inclusion as a long-duration volume lever that does not depend on visit recovery. International CAG diagnostics recurring revenues grew nearly 12% …
20% of CancerDx test volumes come from practices using a competitive laboratory, indicating clear share gains from competitors.